On today's episode we talk with popular guest Dr. Chris Booth of Queen's University in Kingston, Ontario, Canada about mapping out a career path after medical school and about his new paper out now in JAMA Oncology titled "Evolution of the Randomized Clinical Trial in the Era of Precision Oncology".

The Oncology RCT: doi.org/10.1001/jamaoncol.2021.0379

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.57 Career Paths and Evolution of the Oncology Randomized Clinical Trial with Dr. Christopher Booth

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

3.57 Career Paths and Evolution of the Oncology Randomized Clinical Trial with Dr. Christopher Booth

Download our free app to listen on your phone